Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Strikes Agreements With Roche Molecular, Eos Biotech


SANTA CLARA, Calif.--GeneChip developer Affymetrix here and Roche Molecular Systems announced a joint effort to develop and market a new generation of diagnostic tests that combines Affymetrix's GeneChip DNA probe array technology with Roche's PCR gene amplification technology. The companies will initially develop diagnostic kits for applications in HIV drug resistance. The agreement provides a framework for the development of additional GeneChip diagnostic kits as the parties identify further product opportunities.

Affymetrix also signed a series of agreements with Eos Biotechnology granting the South San Francisco startup access to custom and standard GeneChip expression arrays for application to Eos's molecular genomics research efforts in specific fields of cancer, inflammation, and cardiovascular disease. Eos will be able to purchase several thousand GeneChip probe arrays over the next 30 months. In exchange, Affymetrix will receive Series C preferred stock, gaining an ownership position in Eos of approximately 15 percent.

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.